ITALIEN

Mintlayer Token Ticker Is Changing From MLT to ML

Retrieved on: 
Saturday, March 11, 2023
Bitcoin, Decentralized finance, Defi, Ecosystem, ML, TGE, MLT, BTC, Cryptocurrency

San Marino | March 09, 2023 09:58 AM Eastern Standard Time

Key Points: 
  • San Marino | March 09, 2023 09:58 AM Eastern Standard Time
    Mintlayer, a layer-2 solution that aims to bring decentralized finance (DeFI) to Bitcoin, has changed the ticker for its ML Token from MLT to ML ahead of its upcoming token generation event (TGE) on March 21 .
  • The ticker change reflects Mintlayer’s commitment to providing a simple and intuitive platform for its users.
  • Mintlayer has made the change to create a new unique ticker for the upcoming token launch.
  • Gate.io, one of the world’s largest centralized cryptocurrency exchanges worldwide by volume, will list the ML Token on March 21 and the token will become available for public trading on the exchange on March 23.

EQS-News: Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

Retrieved on: 
Wednesday, February 22, 2023
XETRA, Manhattan Psychiatric Center, Psychiatry, PANSS, Positive, Safety, Patient, Nathan Kline Institute for Psychiatric Research, CNS, Peripheral nervous system, CET, Psychosis, Congress, TRS, Disease, Clozapine, Schizophrenia International Research Society, European, Headache, Clinical Global Impression, Pharmaceutical industry, Newron Cup, Research

Results from these same 100 patients at six weeks and six months in study 014/015 have been reported previously.

Key Points: 
  • Results from these same 100 patients at six weeks and six months in study 014/015 have been reported previously.
  • Further evidence of the progressive benefit over time was evident from the growing proportion of patients rated “very much improved” at one year.
  • These Phase II, open-label data of evenamide in patients with TRS, obtained with blinded raters, are very promising.
  • The company continues its dialogue with industry partners around potential future collaboration opportunities for the development of evenamide.

Play-and-Earn Football Prediction App Pooky Announces Availability Of Genesis NFT Collection

Retrieved on: 
Wednesday, February 22, 2023
Mechanics, Formula, Sega Genesis Collection, Basketball, TPK, Red Bull, Spotify, Football, POK, Collection, MATIC, Nike, NFT, Gambling, Tennis, Cryptocurrency, Pooky

Pooky , the gamified Web3 football prediction platform, has launched its Genesis Collection Pookyball NFTs for early access to its gamified, no-risk alternative to betting.

Key Points: 
  • Pooky , the gamified Web3 football prediction platform, has launched its Genesis Collection Pookyball NFTs for early access to its gamified, no-risk alternative to betting.
  • With Pookyball NFTs, players will be empowered to earn crypto-based rewards for guessing the outcomes of football matches in Europe’s biggest football leagues.
  • Pooky is transforming sports betting with a unique NFT-based prediction game that provides the same thrills, but without the financial risks of traditional gambling.
  • Pooky’s prediction game initially supports football, with plans to expand to tennis, basketball and Formula 1 later this year.

TaTaTu S.p.A.: COMPLETION OF THE SHARE CAPITAL INCREASE RESOLVED BY THE EXTRAORDINARY SHAREHOLDERS’ MEETING HELD ON 20 DECEMBER 2022

Retrieved on: 
Thursday, February 2, 2023
TaTaTu, OR, Regulatory News Service, Public offering, Disclosure, Security (finance)

1,325,000 ordinary shares with voting rights, offered for subscription to Anivad Consulting Ltd, a company whose major shareholder is Eduardo Teodorani Fabbri, have been fulfilled.

Key Points: 
  • 1,325,000 ordinary shares with voting rights, offered for subscription to Anivad Consulting Ltd, a company whose major shareholder is Eduardo Teodorani Fabbri, have been fulfilled.
  • Such transaction, amounting to Euro 2,650,000.00, has already been described in the press releases dated 11 November 2022 and 20 December 2022.
  • Therefore, on the date hereof, the share capital shall be increased from an amount equal to Euro 8,142,652.32 to an amount equal to Euro 8,155,902.32 and made of no.
  • The newly issued shares will be admitted to trading as of the second day following the publication of this press release.

TaTaTu S.p.A.: APPROVAL OF THE CAPITAL INCREASE OF THE EXTRAORDINARY GENERAL MEETING ON 20 DECEMBER 2022

Retrieved on: 
Sunday, January 22, 2023
TaTaTu, Public offering, Regulatory News Service, OR, Security (finance)

Dissemination of a French Regulatory News, transmitted by EQS Group.

Key Points: 
  • Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, OR JAPAN
    Rome, December 20, 2022 - Tatatu S.p.A. (the “Company”) that owns TaTaTu, an entertainment platform based on data sharing economy and circular economy, listed through Direct Listing of shares on Euronext Growth Paris (ticker code: ALTTU), informs that the extraordinary shareholders' meeting was held today which approved the capital increase with the exclusion of the pre-emption right with the issue by the company of 1,325,000 ordinary shares in favour of Anivad Consulting Ltd for a value of 2,650,000 euros.

EQS-News: Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

Retrieved on: 
Sunday, January 22, 2023
Neuroscience, Peripheral nervous system, CET, Clozapine, Newron Cup, Semel Institute for Neuroscience and Human Behavior, Education, Evenamide, Clinical Global Impression, CNS, Patient, Safety, XETRA, UCLA, Congress, PANSS, TRS, Positive, European, Pharmaceutical industry, Psychiatry

85 of the 100 patients completed the 30-week treatment period with evenamide.

Key Points: 
  • 85 of the 100 patients completed the 30-week treatment period with evenamide.
  • The proportion of patients demonstrating a clinically meaningful PANSS improvement (“responders”) at week 30 more than doubled from 16.5% at week six.
  • The addition of evenamide to the current antipsychotic medication of the patients continued to be well tolerated after six months of treatment.
  • Evenamide was well tolerated with few adverse effects and 85 of 100 patients remained on treatment at 30 weeks.

TaTaTu S.p.A.: Payment of euro 6.5 million for future capital increases by IA Media SA

Retrieved on: 
Sunday, January 22, 2023
TaTaTu, Finance, Regulatory News Service, OR, Public offering, Security (finance)

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • The agreement does not provide for charges and guarantees to be borne by the Company.
  • Tatatu also informs that Dr. Ribechi replaced the resigned Francesca Brusco as member of board of statutory auditor.
  • This press release is available on the Company's website at the following address https://corporate.tatatu.com/en/corporate/ Financial Press Releases.